Wibke Stansen

1.4k total citations
41 papers, 929 citations indexed

About

Wibke Stansen is a scholar working on Pulmonary and Respiratory Medicine, Rheumatology and Physiology. According to data from OpenAlex, Wibke Stansen has authored 41 papers receiving a total of 929 indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Pulmonary and Respiratory Medicine, 9 papers in Rheumatology and 7 papers in Physiology. Recurrent topics in Wibke Stansen's work include Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (34 papers), Eosinophilic Disorders and Syndromes (9 papers) and Sarcoidosis and Beryllium Toxicity Research (7 papers). Wibke Stansen is often cited by papers focused on Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis (34 papers), Eosinophilic Disorders and Syndromes (9 papers) and Sarcoidosis and Beryllium Toxicity Research (7 papers). Wibke Stansen collaborates with scholars based in Germany, France and United States. Wibke Stansen's co-authors include Susanne Stowasser, Manuel Quaresma, Michael Kreuter, Wim Wuyts, Bruno Crestani, John T. Huggins, Luca Richeldi, Ganesh Raghu, Dominique Valeyre and Ulrich Costabel and has published in prestigious journals such as American Journal of Respiratory and Critical Care Medicine, CHEST Journal and European Respiratory Journal.

In The Last Decade

Wibke Stansen

34 papers receiving 901 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Wibke Stansen Germany 15 774 352 141 105 79 41 929
Ferhan Özşeker Türkiye 12 117 0.2× 233 0.7× 119 0.8× 5 0.0× 60 0.8× 33 508
Luis Salinas‐Madrigal United States 14 200 0.3× 67 0.2× 54 0.4× 19 0.2× 73 0.9× 39 656
T. G. Villar Portugal 7 195 0.3× 216 0.6× 42 0.3× 22 0.2× 18 0.2× 14 372
Natália Melo Portugal 15 514 0.7× 235 0.7× 41 0.3× 3 0.0× 24 0.3× 86 718
Gianfranco Rizzato Italy 11 277 0.4× 339 1.0× 37 0.3× 5 0.0× 23 0.3× 17 597
Robert B. Dreisin United States 9 382 0.5× 85 0.2× 31 0.2× 12 0.1× 53 0.7× 13 609
Tatsuo Yoneda Japan 12 160 0.2× 41 0.1× 40 0.3× 10 0.1× 47 0.6× 75 430
Atsuhiko Tada Japan 11 236 0.3× 100 0.3× 12 0.1× 21 0.2× 21 0.3× 43 536
Steven M. Weiss United States 10 169 0.2× 117 0.3× 20 0.1× 6 0.1× 22 0.3× 24 484
Jae Seung Soh South Korea 15 222 0.3× 23 0.1× 63 0.4× 14 0.1× 31 0.4× 51 662

Countries citing papers authored by Wibke Stansen

Since Specialization
Citations

This map shows the geographic impact of Wibke Stansen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wibke Stansen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wibke Stansen more than expected).

Fields of papers citing papers by Wibke Stansen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wibke Stansen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wibke Stansen. The network helps show where Wibke Stansen may publish in the future.

Co-authorship network of co-authors of Wibke Stansen

This figure shows the co-authorship network connecting the top 25 collaborators of Wibke Stansen. A scholar is included among the top collaborators of Wibke Stansen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wibke Stansen. Wibke Stansen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Wells, Athol U., Nicola Sverzellati, Luca Richeldi, et al.. (2023). Associations Between Semi-quantitative HRCT Features and Outcomes in Patients With IPF: Data From the INPULSIS Trials. A1122–A1122.
3.
4.
Bonella, Francesco, Wim Wuyts, Carlo Vancheri, et al.. (2022). Effects of nintedanib in patients with idiopathic pulmonary fibrosis and varying severities of cough*. Pneumologie. 76(S 01). S20–S21. 1 indexed citations
5.
Glaspole, Ian, Francesco Bonella, Elena Bargagli, et al.. (2021). Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis who are elderly or have comorbidities. Respiratory Research. 22(1). 125–125. 24 indexed citations
6.
Wijsenbeek, Marlies, Paolo Spagnolo, Martin Kolb, et al.. (2021). Do worse scores on patient-reported outcomes predict the progression of interstitial lung disease (ILD)?. PA3748–PA3748.
7.
Kreuter, Michael, Wim Wuyts, Marlies Wijsenbeek, et al.. (2020). Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trials. Respiratory Research. 21(1). 36–36. 32 indexed citations
8.
Jouneau, S., Bruno Crestani, Ronan Thibault, et al.. (2020). Analysis of body mass index, weight loss and progression of idiopathic pulmonary fibrosis. Respiratory Research. 21(1). 312–312. 47 indexed citations
9.
Song, Jin Woo, Takashi Ogura, Yoshikazu Inoue, et al.. (2019). Long‐term treatment with nintedanib in Asian patients with idiopathic pulmonary fibrosis: Results from INPULSIS®‐ON. Respirology. 25(4). 410–416. 30 indexed citations
10.
Richeldi, Luca, Bruno Crestani, Arata Azuma, et al.. (2019). Outcomes following decline in forced vital capacity in patients with idiopathic pulmonary fibrosis: Results from the INPULSIS and INPULSIS-ON trials of nintedanib. Respiratory Medicine. 156. 20–25. 19 indexed citations
11.
Jouneau, S., Bruno Crestani, Ronan Thibault, et al.. (2019). Relationship between body mass index (BMI) and decline in FVC in patients with IPF. HAL (Le Centre pour la Communication Scientifique Directe). PA2252–PA2252.
12.
Brown, Kevin M., Kevin R. Flaherty, Vincent Cottin, et al.. (2018). Lung function outcomes in the INPULSIS® trials of nintedanib in idiopathic pulmonary fibrosis. Respiratory Medicine. 146. 42–48. 26 indexed citations
13.
Costabel, Ulrich, Jürgen Behr, Bruno Crestani, et al.. (2018). Anti-acid therapy in idiopathic pulmonary fibrosis: insights from the INPULSIS® trials. Respiratory Research. 19(1). 167–167. 29 indexed citations
14.
Kreuter, Michael, J.C. Grutters, Luca Richeldi, et al.. (2018). Pharmacokinetics (PK) of nintedanib with add-on pirfenidone in patients with idiopathic pulmonary fibrosis (IPF): results from INJOURNEY. Pneumologie. 72(S 01). S46–S46. 1 indexed citations
15.
Vancheri, Carlo, Michael Kreuter, Luca Richeldi, et al.. (2017). Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial. American Journal of Respiratory and Critical Care Medicine. 197(3). 356–363. 208 indexed citations
16.
Wuyts, Wim, Martin Kolb, Susanne Stowasser, et al.. (2016). First Data on Efficacy and Safety of Nintedanib in Patients with Idiopathic Pulmonary Fibrosis and Forced Vital Capacity of ≤50 % of Predicted Value. Lung. 194(5). 739–743. 90 indexed citations
17.
Swigris, Jeffrey J., Dirk Eßer, Hilary Wilson, et al.. (2016). Psychometric properties of the St George's Respiratory Questionnaire in patients with idiopathic pulmonary fibrosis. European Respiratory Journal. 49(1). 1601788–1601788. 39 indexed citations
18.
Maher, Toby M., Kevin R. Flaherty, Yoshikazu Inoue, et al.. (2016). No effect of baseline diffusing capacity of lung for carbon monoxide on benefit of nintedanib. OA4959–OA4959. 5 indexed citations
19.
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ferhan Özşeker Breakdown of academic impact, for papers by Luis Salinas‐Madrigal Breakdown of academic impact, for papers by T. G. Villar Breakdown of academic impact, for papers by Natália Melo Breakdown of academic impact, for papers by Gianfranco Rizzato Breakdown of academic impact, for papers by Robert B. Dreisin Breakdown of academic impact, for papers by Tatsuo Yoneda Breakdown of academic impact, for papers by Atsuhiko Tada Breakdown of academic impact, for papers by Steven M. Weiss Breakdown of academic impact, for papers by Jae Seung Soh
Rankless by CCL
2026